Anavex Life Sciences Corp. (AVXL): Price and Financial Metrics
AVXL Price/Volume Stats
| Current price | $3.68 | 52-week high | $10.45 |
| Prev. close | $3.78 | 52-week low | $3.60 |
| Day low | $3.64 | Volume | 1,358,500 |
| Day high | $3.85 | Avg. volume | 1,437,614 |
| 50-day MA | $4.91 | Dividend yield | N/A |
| 200-day MA | $6.62 | Market Cap | 302.18M |
AVXL Stock Price Chart Interactive Chart >
Anavex Life Sciences Corp. (AVXL) Company Bio
Anavex Life Sciences Corporation is engaged in the discovery and development of drugs for the treatment of Alzheimers disease, central nervous system diseases, and pain and various cancers. The company was founded in 2006 and is based in New York, New York.
Latest AVXL News From Around the Web
Below are the latest news stories about ANAVEX LIFE SCIENCES CORP that investors may wish to consider to help them evaluate AVXL as an investment opportunity.
Anavex (AVXL) Rises as CHMP Deems Blarcamesine Eligible for MAAThe CHMP agrees that Anavex's (AVXL) blarcamesine for Alzheimer's disease is eligible for submission for a Union Marketing Authorisation in the EU. Shares rise. |
Anavex Life Sciences Stock Sees RS Rating Jump To 86; Is It One To Watch?Anavex Life Sciences now clears that threshold, with a jump from 66 to 86 Wednesday. IBD's unique rating identifies price performance with a 1 (worst) to 99 (best) score. Over 100 years of market history shows that the market's biggest winners often have an RS Rating of above 80 as they begin their biggest price moves. |
Anavex Announces First Entire Clinical Gene Pathway Data of ANAVEX®2-73 from AVATAR Study in Patients with Rett SyndromeSignificant activation of key developmental and metabolic gene pathways and potential compensatory mechanism with ANAVEX®2-73 in Rett syndrome patients Heatmap Heatmap NEW YORK, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndro |
Anavex Received Agreement from the Committee for Medicinal Products for Human Use (CHMP) for the Submission of a Marketing Authorisation Application of Oral Blarcamesine for Alzheimer’s DiseaseNEW YORK, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders, announced today that the Committee for Medicinal Products for Human Use (CHMP) within the European Medicines Agency (EMA) agreed that oral blarcamesine for Alzheimer’s disease is eligible for submission of an application for a Uni |
Does Anavex Life Sciences (AVXL) Have the Potential to Rally 401.47% as Wall Street Analysts Expect?The average of price targets set by Wall Street analysts indicates a potential upside of 401.5% in Anavex Life Sciences (AVXL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
AVXL Price Returns
| 1-mo | -21.03% |
| 3-mo | -44.07% |
| 6-mo | -34.52% |
| 1-year | -53.12% |
| 3-year | -69.21% |
| 5-year | 25.17% |
| YTD | -60.47% |
| 2023 | 0.54% |
| 2022 | -46.60% |
| 2021 | 221.11% |
| 2020 | 108.49% |
| 2019 | 66.03% |
Loading social stream, please wait...